Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof

1. A process for producing an active compound product of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate of formula (I)

in the crystalline form of modification I, wherein the x-ray diffractogram of the compound of the formula (I) in modification I exhibits peak maxima of the 2 theta angle at 5.9, 6.9, 22.7, comprising:

a) dissolving the compound of formula (I) in solid form at a temperature of 30-100° C. in one or more polar and/or aprotic solvents or in one or more polar and/or aprotic solvents in combination with at least one wetting agent selected from the group consisting of methanol, ethanol, n-propanol, and isopropanol,

b) subsequently crystallizing the dissolved compound of formula (I) out of the solution by adding water as antisolvent or of water in combination with at least one wetting agent selected from the group consisting of methanol, ethanol, n-propanol, and isopropanol, wherein the ratio of water to the at least one wetting agent added in step a) or b) is 1:0-20:1 w/w and the addition of water or of the combination of water with at least one wetting agent is carried out at a temperature of 30-100° C. and over a duration of 0.1 min-1200 min,

or

initially charging water as antisolvent or water in combination with at least one wetting agent and adding the compound of formula (I) dissolved according to step a), wherein the at least one wetting agent, the ratio of water to the at least one wetting agent added in step a) and/or b), the temperature and the duration over which the addition of the dissolved compound is carried out are as specified above;

c) subsequently cooling the suspension formed to a temperature of 5-50° C. at a cooling rate of 1-60 K/h; and

d) subsequently agglomerating the crystals formed in step b) to afford active compound product by adding an agglomeration liquid, wherein in the case where a wetting agent was added in step a) and/or b) the ratio of the mass of the agglomeration liquid to the sum of the mass of the compound of formula (I) plus the mass of the at least one wetting agent added in step a) and/or b) is 0.3 to 2.0.

2. The process according to claim 1 , wherein the at least one polar and/or aprotic solvent in step a) is selected from the group consisting of DMSO, N-methyl-2-pyrrolidone (NMP), dimethylacetamide (DMAc) and dimethylformamide (DMF) or combinations thereof with at least one wetting agent selected from the group consisting of methanol, ethanol, n-propanol, and isopropanol.

3. The process according to claim 1 , wherein step a) employs DMSO as solvent in combination with ethanol as wetting agent, wherein the ratio between DMSO and ethanol is 1:0 to 5:1 w/w.

4. The process according to claim 1 , further comprising following step a) by a filtration.

5. The process according to claim 1 , wherein step b) comprises crystallizing the dissolved compound of formula (I) out of the solution by adding water as antisolvent or water in combination with at least one wetting agent selected from the group consisting of methanol, ethanol, n-propanol and isopropanol, wherein the ratio of water to the at least one wetting agent added in step a) or b) is 1:0-12:1 w/w and the addition of water or of the combination of water with at least one wetting agent is carried out at a temperature of 50-90° C. and over a period of 0.1 min-360 min,

or

initially charging water as antisolvent or water in combination with at least one wetting agent and adding the compound of formula (I) dissolved according to step a), wherein the at least one wetting agent, the ratio of water to the at least one wetting agent added in step a) and/or b), the temperature and the duration over which the addition of the dissolved compound is carried out are as specified above.

6. The process according to claim 1 , wherein step c) comprises cooling the suspension formed to a temperature of 10-30° C. at a cooling rate of 5-45 K/h.

7. The process according to claim 1 , wherein the agglomeration liquid employed in step d) is selected from the group consisting of methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, and isobutyl acetate.

8. The process according to claim 1 , further comprising step e) of isolating and drying the active compound product formed in step d), wherein step e) comprises washing the active compound product after isolation initially with a C 1 -C 4 alcohol and subsequently with an acetate selected from methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate and isobutyl acetate and subsequently drying the active compound product under reduced pressure with a nitrogen stream at a temperature of 15-75° C.

9. The process according to claim 8 , further comprising step f) of comminuting the active compound product after isolation and drying.

10. An active compound product of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b] pyridin-3-yl] pyrimidin-5-yl}carbamate of the compound of formula (I) in the crystalline form of modification I produced by the process according to claim 1 .

11. The active compound product according to claim 10 , wherein the active compound product has one or more of the following properties compared to the properties of a comparator active compound product of the compound of formula (I) in the crystalline form of modification I produced by the process of route 1, the properties selected from an elevated average area-specific throughput for isolation using a centrifuge with a batch size of >10 kg of active compound product, a higher maximum filtercake thickness at which the discharge path out of an inverting filter centrifuge does not become blocked, an elevated sieve throughput with a batch size of >10 kg of active compound product, and a shortened incorporation time required to introduce the active compound product into a granulating suspension before homogenization thereof,

wherein the process of route 1 comprises the steps of preparing the compound of formula (I) from the di-dimethyl sulphoxide solvate thereof by stirring in ethyl acetate/ethanol at reflux, cooling, then filtering without (1) crystallizing a dissolved compound of formula (I) out of solution by contact with water as an antisolvent or water with a wetting agent, (2) subsequently cooling and (3) subsequently agglomerating crystals formed by adding an agglomeration liquid.

12. The active compound product produced by the process according to claim 8 , wherein after the isolating and drying in step e) the active compound product contains no DMSO.

13. A solid dosage form containing active compound product of the compound of formula (I) produced by the process according to claim 1 and further containing microcrystalline cellulose, lactose monohydrate, hydroxypropylmethylcellulose 3 cP and/or 5 cP, sodium lauryl sulfate or polysorbate 20, sodium croscarmellose, magnesium stearate, talc, iron oxides and titanium dioxide.